MerckMRK
MRK
About: Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Employees: 75,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
11% more call options, than puts
Call options by funds: $2.57B | Put options by funds: $2.32B
1.5% less ownership
Funds ownership: 77.9% [Q4 2024] → 76.41% (-1.5%) [Q1 2025]
5% less funds holding
Funds holding: 3,544 [Q4 2024] → 3,360 (-184) [Q1 2025]
10% less funds holding in top 10
Funds holding in top 10: 71 [Q4 2024] → 64 (-7) [Q1 2025]
10% less capital invested
Capital invested by funds: $196B [Q4 2024] → $176B (-$20.3B) [Q1 2025]
16% less repeat investments, than reductions
Existing positions increased: 1,314 | Existing positions reduced: 1,563
36% less first-time investments, than exits
New positions opened: 176 | Existing positions closed: 274
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$84
3%
upside
Avg. target
$95
16%
upside
High target
$115
41%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Citigroup Andrew Baum | 3%upside $84 | Neutral Downgraded | 14 May 2025 |
Cantor Fitzgerald Carter Gould | 4%upside $85 | Neutral Initiated | 22 Apr 2025 |
Guggenheim Vamil Divan | 41%upside $115 | Buy Reiterated | 17 Apr 2025 |
Financial journalist opinion
Based on 63 articles about MRK published over the past 30 days
Negative
The Motley Fool
23 hours ago
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
The Dow Jones Industrial Average (^DJI -1.79%) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ending the month in positive territory. However, the two worst-performing Dow stocks in May -- both from the healthcare sector -- kept the index's rally in check, with one of them plunging over 25%.
Positive
Investopedia
1 day ago
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck (MRK) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda.
Neutral
Business Wire
2 days ago
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, con.
Neutral
Business Wire
2 days ago
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs. NUMELVI, a once-daily, first-line treatment, will be the only second-generation Janus kinase (JAK) inhibitor indicated for the treatmen.
Positive
Yahoo Finance
2 days ago
5 stocks to consider right now amid volatility and uncertainty: Portfolio manager
Market volatility can be scary for investors, but it can also bring opportunity. In the video above, Kovitz Investment Group portfolio manager John Buckingham explains why investors should be "embracing volatility.
Neutral
Reuters
2 days ago
Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck's Gardasil vaccine, court records show.
Neutral
Business Wire
2 days ago
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements.
Neutral
Business Wire
3 days ago
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the.
Negative
Zacks Investment Research
3 days ago
Here's Why Merck (MRK) Fell More Than Broader Market
In the most recent trading session, Merck (MRK) closed at $80.32, indicating a -1.27% shift from the previous trading day.
Positive
Zacks Investment Research
3 days ago
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
Charts implemented using Lightweight Charts™